| Recruitment status | Preinitiation |
| Unique ID issued by UMIN | UMIN000035382 |
| Receipt No. | R000040313 |
| Official scientific title of the study | Compare the efficacy of diagnostic treatment with P-CAB and PPI before to do endoscopy for GERD patients. |
| Date of disclosure of the study information | 2019/03/01 |
| Last modified on | 2018/12/27 (Ver. 1) |
| Basic information | ||
| Official scientific title of the study | Compare the efficacy of diagnostic treatment with P-CAB and PPI before to do endoscopy for GERD patients. | |
| Title of the study (Brief title) | Compare the efficacy of treatment with P-CAB and PPI in patients with GERD. | |
| Region |
|
|
| Condition | ||
| Condition | Gastroesophageal reflux disease | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To compare the efficacy of Vonoprazan(20mg/day) vs Esomeprazole(20mg/day) for 1week treatment in patients with GERD by assessing the time(days) to be GERD symptom relief before to do endoscopy. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Time(days) to GERD symptom relief. |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Single blind -participants are blinded |
| Control | Active |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Vonoprazan(Takecab)20mg once a day in the mornimg. | |
| Interventions/Control_2 | Esomeprazole(Nexium)20mg once a day in the mornimg. | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1.Patients whose chief complain are heartburn or acetic acid more than 2days in a week.
2.Patients who are at least 20 years of age. 3.Patients whose main organs work. 4.Patients who have given written consent to participate in the study. |
|||
| Key exclusion criteria | 1.Patients with a history of hypersensitivity to components of Vonoprazan and Esomeprazole.
2.Patients taking PPI including Vonoprazan and Esomeprazole. 3.Patients taking Atazanavir sulfate and Rilpivirine hydrochloride. 4.Patients who are diagnosed Zollinger-Ellison syndrome and Pernicious anemia. 5.Patients who have complicated other severe diseases and whose clinical trials can not be safety performed or whose effect judgment is difficult. 6.Patients with malignant tumor complications. 7.Patients with a history of surgery of the upper gastrointestinal tract including the stomach and esophagus. 8.Patients who may be pregnant or pregnant. 9.Patients who judged by physician inappropriate to participate in clinical trials. |
|||
| Target sample size | 100 | |||
| Research contact person | |
| Name of lead principal investigator | Akihiro Tamaki |
| Organization | Kitasato University |
| Division name | Internal gastroenterology |
| Address | 1-15-1 Kitasato Minami,Sagamihara,Kanagawa,Japan |
| TEL | 042-778-8111 |
| a.tamaki@kitasato-u.ac.jp | |
| Public contact | |
| Name of contact person | Kengi Ishido |
| Organization | Kitasato University |
| Division name | Internal gastroenterology |
| Address | 1-15-1 Kitasato Minami,Sagamihara,Kanagawa,Japan |
| TEL | 042-778-8111 |
| Homepage URL | |
| k.ishido@kitasato-u.ac.jp | |
| Sponsor | |
| Institute | Kitasato University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | None |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Preinitiation | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040313 |